Neurizon appoints Dr Chris Bremer as CEO

7 September 2026

Australian late-stage biotech Neurizon Therapeutics (ASX: NUZ; OTCQB: NUZTF) today announced the appointment of Dr Chris Bremer as chief executive (CEO), effective October1, 2026.

His appointment comes as Neurizon advances NUZ-001 through Regimen I of the registrational Phase II/III HEALEY ALS Platform Trial and enters the important period leading up to top-line results, expected in late second quarter 2027. His combination of scientific, medical, commercial and transactional experience is particularly relevant as the Company prepares for the potential regulatory, development and strategic pathways that may follow and seeks to create long-term shareholder value, Neurizon noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK